NCT03692052Phase 2Active not recruiting

A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia

Study sponsor: Agios Pharmaceuticals, Inc. · AGIO

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2020-08-20Actual
Enrollment · participants20Actual
Source updated2026-03-30Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.